Navigation Links
New test discovered to better predict breast cancer outcomes
Date:1/27/2011

Researchers from McGill University's Rosalind and Morris Goodman Cancer Research Centre (GCRC), the Research Institute of the McGill University Health Centre (RI MUHC), the DanaFarber Cancer Institute and Harvard Medical School have discovered a gene signature that can accurately predict which breast cancer patients are at risk of relapse, thereby sparing those who are not from the burdens associated with unnecessary treatment.

For years, clinicians have been faced with the problem that breast cancer cannot be treated with a one-size-fits-all approach. Some cancers respond to specific treatments while others do not. Close to 50 per cent of breast cancer patients belong to a group defined as "estrogen receptor positive/lymph node negative (ER+/LR-)" that is at low risk of relapse. The majority of patients in this group may not require any treatment beyond the surgical removal of their tumour, while a small minority should receive additional treatment.

"The added information provided by our test would enable oncologists to identify those at very low risk of relapse, for whom the risk-benefit ratio might be in favour of withholding chemotherapy, and to identify patients in this low-risk group who would benefit from more aggressive treatments," explains Dr. Alain Nepveu, GCRC and RI MUHC researcher and co-author of the study. "Since many treatments are associated with short- and long-term complications including premature menopause, cardiotoxicity and the development of secondary cancers, risks must be balanced against the potential benefit for each patient to avoid unnecessary suffering, needless expense and added burdens on the health-care system."

While more research is required before the test would be ready for market and incorporated into existing diagnostic procedures, Nepveu suggests it has the potential to be commercialized within five years.


'/>"/>

Contact: Allison Flynn
allison.j.flynn@mcgill.ca
514-972-3934
McGill University
Source:Eurekalert

Page: 1

Related medicine news :

1. First Gene Variants Linked to Stuttering Discovered
2. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
3. Genes Behind Tooth Development Discovered
4. Genetic cause discovered for rare bleeding disorder
5. Gene discovered for newly recognized disease in Amish children
6. Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center
7. Genetic pattern that predicts leukemia relapse discovered
8. Researchers report new autism genes discovered
9. New function discovered in cancer-prevention protein
10. New strain of bacteria discovered that could aid in oil spill, other environmental cleanup
11. Early detection of cancer: The FDA approves procedure discovered by EPFL researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Pa. , June 23, 2016 The ... in an outpatient dialysis facility.  Treatments are usually 3 ... 6 hours per visit, including travel time, equipment preparation ... a patient, but especially grueling for patients who are ... of a skilled nursing and rehabilitation centers for some ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
(Date:6/23/2016)... -- The National Pharmaceutical Council (NPC) today announced that ... organization as its newest member.  ... and chief scientific officer, Mallinckrodt Pharmaceuticals, will serve ... of Directors. ... in support of our efforts to conduct research ...
Breaking Medicine Technology: